Navigation Links
Cholesterol-lowering drug linked to sleep disruptions
Date:11/7/2007

ORLANDO, Nov. 7 A cholesterol-lowering drug appears to disrupt sleep patterns of some patients, researchers reported at the American Heart Associations Scientific Sessions 2007.

The findings are significant because sleep problems can affect quality of life and may have adverse health consequences, such as promoting weight gain and insulin resistance, said Beatrice Golomb, M.D., lead author of the study and an associate professor of medicine and family and preventive medicine at the University of California at San Diego School of Medicine.

In the largest study of its kind, researchers compared two types of cholesterol-lowering drugs called statins simvastatin, which is lipophilic (soluble in fats), and pravastatin, which is hydrophilic (soluble in water).

Because simvastatin is fat soluble it can more readily penetrate cell membranes and cross the blood brain barrier into the brain. The brain controls sleep, and many of the brains nerve cells are wrapped in a fatty insulating sheath called myelin.

The results showed that simvastain use was associated with significantly worse sleep quality. A significantly greater number of individuals taking simvastatin reported sleep problems than those taking either pravastain or the placebo, Golomb said. On average, the lipophilic statin had a greater adverse effect on sleep quality.

In past studies and case reports, some people on statins reported having insomnia or nightmares.

Several small studies were done early on, including those focused on lipophilic versus hydrophilic statins, Golomb said. Most (researchers) didnt see a difference in sleep, but they had short durations of follow-up and enrolled just a handful of people often fewer than 20, which was not enough to see a difference unless it was very large.

One of these studies did report a significant difference between pravastatin and simvastatin. But without more and bigger studies, an effect was not considered to be established.

In this study, researchers tested 1,016 healthy adult men and women for six months in a randomized, double-blind, placebo-controlled trial using simvastatin, given at 20 milligrams (mg), pravastatin at 40 mg, or a placebo. They assessed outcomes with the Leeds sleep scale, a visual analog scale of sleep quality, and a rating scale of sleep problems. Both scales were measured before and during treatment.

Those who reported developing much worse sleep on study medication also showed a significant adverse change in aggression scores compared to others, Golomb said We should also point out that although the average effect on sleep was detrimental on simvastatin, this does not mean that everyone on simvastatin will experience worse sleep.

Researchers did not include patients with heart disease or diabetes due to concerns about assigning these people to placebos.

Patients taking simvastatin who are having sleep problems should consult with their doctor, Golomb said. Sleep deprivation is a major problem in a minor number of people.


'/>"/>

Contact: Karen Astle
karen.astle@heart.org
214-706-1392
American Heart Association
Source:Eurekalert

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
3. Immune deficiency linked to a type of eye cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Clinical depression linked to abnormal emotional brain circuits
6. Air pollution linked to cardiovascular risk indices in healthy young adults
7. High pollution linked to poor lung function growth in children in Mexico City
8. Early Weight Loss in Women Linked to Dementia
9. Vitamin Es lack of heart benefit linked to dosage
10. Sugary Sodas High in Diabetes-Linked Compound
11. RA Drugs Linked to Slight Skin Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... For over twenty-four years, Doctors on Liens has published a directory of the ... medical care. When the company started in 1997, the directory was a single page ... the now ten-page directory features a vast array of medical specialists stretching from ...
(Date:12/2/2016)... ... 02, 2016 , ... FlexiSpot, a trusted name in sit-stand ... program for all of the company’s desktop riser products. A simple application form ... , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering system ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the ... how he was inspired to practice medicine at an early age by his father, ... than making diagnoses and prescribing medicine,” he states. “It is about building relationships with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a ... in the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. ... their education, experience, and professional associations. , One the most frequently honored ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Md. , Dec. 2, 2016 The ... indication for Jardiance (empagliflozin) to reduce the risk of ... mellitus and cardiovascular disease. "Cardiovascular disease ... type 2 diabetes mellitus," said Jean-Marc Guettier , ... Endocrinology Products in FDA,s Center for Drug Evaluation and ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
(Date:12/2/2016)... , December 2, 2016 ... Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), ... (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast ... is valued at USD 60.22 Billion in 2016. ... CAGR of 5.5% during the forecast period (2016-2021) ...
Breaking Medicine Technology: